Market Cap | 306.58M | P/E | - | EPS this Y | -15.40% | Ern Qtrly Grth | - |
Income | -135.38M | Forward P/E | -2.79 | EPS next Y | 51.10% | 50D Avg Chg | -2.00% |
Sales | 4.39M | PEG | -0.85 | EPS past 5Y | - | 200D Avg Chg | -14.00% |
Dividend | N/A | Price/Book | 1.66 | EPS next 5Y | 2.40% | 52W High Chg | -59.00% |
Recommedations | 2.20 | Quick Ratio | 0.88 | Shares Outstanding | 292.64M | 52W Low Chg | 48.00% |
Insider Own | 10.18% | ROA | -42.32% | Shares Float | 117.76M | Beta | 1.66 |
Inst Own | 62.30% | ROE | -129.32% | Shares Shorted/Prior | 14.39M/13.12M | Price | 1.20 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,214,056 | Target Price | 6.00 |
Oper. Margin | -3,667.50% | Earnings Date | Nov 7 | Volume | 1,042,734 | Change | -6.98% |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
JMP Securities | Market Outperform | Aug 15, 24 |
HC Wainwright & Co. | Buy | Aug 15, 24 |
JMP Securities | Market Outperform | Jun 4, 24 |
Stifel | Buy | Jun 3, 24 |
HC Wainwright & Co. | Buy | Jun 3, 24 |
Cantor Fitzgerald | Overweight | May 15, 24 |
Stifel | Buy | May 15, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
JP Morgan | Underweight | Mar 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
KIRK RANDAL J | Director Director | Dec 28 | Buy | 1.41 | 96,686 | 136,327 | 1,096,686 | 12/29/23 |
KINDLER JEFFREY B | Director Director | Dec 28 | Sell | 1.41 | 96,686 | 136,327 | 238,275 | 12/29/23 |
Sabzevari Helen | President and CEO President and CEO | Aug 23 | Sell | 1.53 | 76,969 | 117,763 | 1,560,004 | 08/25/23 |
Lehr Donald P. | Chief Legal Officer Chief Legal Officer | Aug 23 | Sell | 1.64 | 10,947 | 17,953 | 428,916 | 08/25/23 |
Shah Rutul R | Chief Operating Offi.. Chief Operating Officer | Aug 23 | Sell | 1.64 | 5,388 | 8,836 | 133,474 | 08/25/23 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | Aug 23 | Sell | 1.64 | 8,891 | 14,581 | 458,903 | 08/25/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Aug 23 | Sell | 1.64 | 9,045 | 14,834 | 161,051 | 08/25/23 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | Aug 16 | Sell | 1.55 | 8,741 | 13,549 | 448,916 | 08/18/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Aug 16 | Sell | 1.55 | 8,893 | 13,784 | 152,162 | 08/18/23 |
Lehr Donald P. | Chief Legal Officer Chief Legal Officer | Aug 16 | Sell | 1.55 | 10,762 | 16,681 | 418,153 | 08/18/23 |
Shah Rutul R | Chief Operating Offi.. Chief Operating Officer | Aug 16 | Sell | 1.55 | 5,298 | 8,212 | 123,382 | 08/18/23 |
Sabzevari Helen | President and CEO President and CEO | Aug 16 | Sell | 1.66 | 55,855 | 92,719 | 1,495,386 | 08/18/23 |
KIRK RANDAL J | Director Director | Aug 15 | Buy | 1.52 | 500,000 | 760,000 | 31,837,786 | 08/17/23 |
Shah Rutul R | Chief Operating Offi.. Chief Operating Officer | Aug 09 | Sell | 1.21 | 5,429 | 6,569 | 113,200 | 08/11/23 |
Lehr Donald P. | Chief Legal Officer Chief Legal Officer | Aug 09 | Sell | 1.21 | 11,026 | 13,341 | 407,205 | 08/11/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Aug 09 | Sell | 1.21 | 6,852 | 8,291 | 143,121 | 08/11/23 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | Aug 09 | Sell | 1.21 | 8,956 | 10,837 | 438,779 | 08/11/23 |
Sabzevari Helen | President and CEO President and CEO | Aug 09 | Sell | 1.44 | 41,436 | 59,668 | 1,409,654 | 08/11/23 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | Aug 02 | Sell | 1.2 | 8,789 | 10,547 | 428,857 | 08/04/23 |
Lehr Donald P. | Chief Legal Officer Chief Legal Officer | Aug 02 | Sell | 1.2 | 10,821 | 12,985 | 396,521 | 08/04/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Aug 02 | Sell | 1.2 | 6,724 | 8,069 | 132,039 | 08/04/23 |
Shah Rutul R | Chief Operating Offi.. Chief Operating Officer | Aug 02 | Sell | 1.2 | 5,328 | 6,394 | 103,149 | 08/04/23 |
Sabzevari Helen | President and CEO President and CEO | Aug 02 | Sell | 1.1 | 52,870 | 58,157 | 1,309,503 | 08/04/23 |
Shah Rutul R | Chief Operating Offi.. Chief Operating Officer | Jan 27 | Buy | 1.75 | 9,142 | 15,998 | 62,037 | 01/30/23 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | Jan 27 | Buy | 1.75 | 28,571 | 49,999 | 381,012 | 01/30/23 |
Sabzevari Helen | President and CEO President and CEO | Jan 27 | Buy | 1.75 | 22,857 | 40,000 | 937,613 | 01/30/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Jan 27 | Buy | 1.75 | 28,571 | 49,999 | 84,961 | 01/30/23 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | Aug 23 | Buy | 2.09 | 24,500 | 51,205 | 56,390 | 08/24/22 |
KINDLER JEFFREY B | Director Director | Aug 11 | Sell | 2.30 | 50,000 | 115,000 | 214,411 | 08/15/22 |
Perez Jeffrey Thomas | SVP, IP Affairs SVP, IP Affairs | May 16 | Sell | 1.28 | 14,778 | 18,916 | 333,502 | 05/18/22 |
Thomasian Harry Jr. | Chief Financial Offi.. Chief Financial Officer | May 16 | Sell | 1.28 | 2,719 | 3,480 | 31,890 | 05/18/22 |
Lehr Donald P. | Chief Legal Officer Chief Legal Officer | May 16 | Sell | 1.28 | 18,196 | 23,291 | 323,274 | 05/18/22 |
Sabzevari Helen | President and CEO President and CEO | May 12 | Sell | 1.19 | 177,968 | 211,782 | 897,091 | 05/16/22 |
KIRK RANDAL J | Director Director | Nov 19 | Buy | 3.61 | 1,000,000 | 3,610,000 | 1,000,000 | 11/23/21 |
Ares Trading S.A. | 10% Owner 10% Owner | Oct 12 | Sell | 4.64 | 143,796 | 667,213 | 20,647,152 | 10/14/21 |
Ares Trading S.A. | 10% Owner 10% Owner | Oct 08 | Sell | 4.68 | 116,204 | 543,835 | 20,790,948 | 10/12/21 |
Ares Trading S.A. | 10% Owner 10% Owner | Oct 06 | Sell | 4.86 | 113,100 | 549,666 | 20,907,152 | 10/08/21 |
Ares Trading S.A. | 10% Owner 10% Owner | Aug 26 | Sell | 5.83 | 78,607 | 458,279 | 21,870,152 | 08/26/21 |